Key points from article :
Halia Therapeutics developed a drug called HT-6184 that targets the NLRP3 inflammasome, a key driver of chronic inflammation linked to numerous diseases.
HT-6184 works by disrupting the formation of the NLRP3 inflammasome and promoting its disassembly, reducing inflammation.
Initial trials showed HT-6184 is safe and effective in healthy volunteers, suppressing inflammatory markers in the blood.
Halia is now testing HT-6184 in Phase 2 trials for various diseases, including myelodysplastic syndromes, arthritis, and chronic inflammatory pain.
Success in myelodysplastic syndromes could have broader implications for ageing, potentially impacting bone marrow health and lifespan.
While not explicitly a "longevity drug," HT-6184's mechanism and potential future applications hold promise for extending healthspan.
